Anastasios Aslidis
About Anastasios Aslidis
Dr. Anastasios (Tasos) Aslidis, 65, has served as an independent director of Cosmos Health (COSM) since April 29, 2022 and is designated an “audit committee financial expert” under SEC rules, reflecting deep finance and governance expertise . He holds a Ph.D. in Ocean Systems Management (MIT, 1989), M.S. in Operations Research (MIT, 1987), M.S. in Ocean Systems Management (MIT, 1984), and a Diploma in Naval Architecture & Marine Engineering (NTUA, 1983) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Marsoft Inc. | Partner | Prior to Euroseas tenure (dates not specified) | Investment and risk management consulting in maritime industry |
| Euroseas (Nasdaq: ESEA) | CFO, Treasurer, Director | Since 2005 | Finance leadership; board service |
| EuroDry (Nasdaq: EDRY) | CFO, Treasurer, Director | Since May 5, 2018 | Finance leadership; board service |
External Roles
| Company | Exchange | Role(s) | Since | Notes |
|---|---|---|---|---|
| EuroDry Ltd. | Nasdaq: EDRY | CFO, Treasurer, Director | 2018-05-05 | Shipping sector |
| Euroseas Ltd. | Nasdaq: ESEA | CFO, Treasurer, Director | 2005 | Shipping sector |
Board Governance
- Committee assignments: Audit Committee member (financial expert); Compensation Committee member; not listed on Nominating & Corporate Governance in latest proxy .
- Independence: Considered independent under Nasdaq and Exchange Act standards; all board committees comprised of independent directors .
- Board leadership: CEO is the only management director; the company has no Lead Independent Director, a governance consideration for investors .
- Attendance: 2024 board and audit attendance were 100% for all directors and committee members; prior years met at least the 75% threshold .
- Audit oversight: Signed audit committee report recommending inclusion of audited financials in Form 10-K (2023 and 2024 fiscal years) .
| Meeting Activity | 2022 | 2023 | 2024 |
|---|---|---|---|
| Board meetings (count) | 10; all directors ≥75% attendance | 15; all directors ≥75% attendance | 2; all directors 100% attendance |
| Audit Committee meetings (count) | 3; 100% attendance | 3; 100% attendance | 1; 100% attendance |
Fixed Compensation
| Year | Cash Fees ($) | Components | Equity Awards ($ FV) | Grant Details | Total ($) |
|---|---|---|---|---|---|
| 2024 | 40,000 | $30,000 board participation; $10,000 committee fee | 20,200 | 20,000 shares granted 9/16/2024 under 2023 Plan | 60,200 |
| 2023 | 60,000 | $50,000 board participation; $10,000 committee fee | 70,600 | 20,000 shares granted 4/3/2023; vest 50% on 10/2/2023 and 50% on 10/2/2024 | 130,600 |
| 2022 | 62,500 | $37,500 director fees + $25,000 bonus for services in 2022 | – | – | 62,500 |
Notes:
- No options reported for directors in 2024; Outstanding Equity Awards table at 12/31/2024 shows no outstanding options or unvested RSUs for Dr. Aslidis .
- Director compensation utilizes cash retainers and restricted share awards; no meeting fees disclosed .
Performance Compensation
- No director performance-based metrics or non-equity incentive plan compensation disclosed for Dr. Aslidis in 2023–2024; 2022 included a discretionary bonus .
| Metric | Weight/Target | Applies to Aslidis? | Notes |
|---|---|---|---|
| Revenue/EBITDA/TSR goals | Not disclosed | No | No director performance metrics disclosed |
| Discretionary bonus | N/A | 2022 only | $25,000 bonus for 2022 services |
Other Directorships & Interlocks
| External Board | Role | Potential Interlock with COSM | Notes |
|---|---|---|---|
| EuroDry (EDRY) | Director; CFO/Treasurer | None disclosed | Different industry (shipping); no related-party dealings disclosed with COSM |
| Euroseas (ESEA) | Director; CFO/Treasurer | None disclosed | Different industry (shipping); no related-party dealings disclosed with COSM |
Expertise & Qualifications
- Audit committee financial expert designation (SEC) .
- 30+ years maritime finance and investment risk management; prior consulting to public/private boards on strategy, asset selection, and investment timing .
- Advanced analytical/technical education (MIT Ph.D., M.S. programs; NTUA engineering diploma) .
Equity Ownership
| Date (Record) | Shares Beneficially Owned | % Outstanding | Source |
|---|---|---|---|
| 2025-08-01 | 40,000 | 0.13% | Beneficial ownership table; 30,127,379 shares outstanding |
| 2023-07-21 | 20,200 | <1% | Beneficial ownership table; 13,068,719 shares outstanding |
Additional alignment and policy notes:
- Anti-hedging and anti-pledging policies are in place (referenced in proxy); no pledging by Dr. Aslidis disclosed .
- No outstanding options or unvested RSUs at 12/31/2024; indicates limited leveraged equity exposure .
Insider Awards/Filings (Section 16)
| Date | Transaction | Shares | Form/Timeliness | Notes |
|---|---|---|---|---|
| 2024-09-16 | Incentive stock award under 2023 Plan | 20,000 | Reported via Form 5 filed 2025-02-12 (late) | Company disclosed late Section 16(a) filings including Aslidis for this award |
| 2023-04-03 | Incentive stock award | 20,000 | Timeliness not flagged | Vested 50% on 10/2/2023 and 50% on 10/2/2024; FV $70,600 |
Governance Assessment
Strengths
- Independent director with robust finance credentials; designated audit committee financial expert; serves on both Audit and Compensation Committees, augmenting board oversight of reporting and pay .
- Strong attendance: 100% in 2024 at board and committee level; prior years at least 75% threshold met .
- Modest, straightforward director pay structure (cash retainers + restricted stock); no options or complex performance plan for directors; 2024 total $60,200 vs. 2023 $130,600 reflecting reduced equity grant value year over year .
Watch items / potential red flags
- Section 16(a) filing deficiency: late reporting of 9/16/2024 stock award, corrected via Form 5 on 2/12/2025. While remedied, timeliness lapses can concern compliance-focused investors .
- Board lacks a Lead Independent Director, concentrating agenda control with CEO-chair structure; investors often prefer a LID in small-caps for enhanced independent oversight .
- Related-party balances (unpaid salary/bonus) with CEO and CFO were disclosed for year-end 2024; while not involving Dr. Aslidis, they elevate overall governance risk posture for COSM’s board to monitor closely .
Related-party/Conflicts
- No related-party transactions involving Dr. Aslidis were disclosed; external roles at EDRY/ESEA (shipping) have no disclosed nexus to COSM’s pharma/distribution business .
Compensation process
- Compensation Committee comprised of independent directors (Hoidas, Aslidis) with Rule 16b-3 “non-employee director” status; charter-based responsibilities to oversee executive pay and incentive plans; no disclosure of external compensation consultant use .
Policy backdrop
- Insider trading, anti-hedging and anti-pledging policies referenced; equity plans updated in 2024 and 2025 (Omnibus) with forfeiture provisions; no director ownership guidelines disclosed .
Overall: Dr. Aslidis adds credible financial oversight and compensation governance to COSM. Key governance improvements investors may seek include appointing a Lead Independent Director and reinforcing Section 16 compliance discipline at the company level .